ResMed Price To Sales Ratio vs Company Equity Multiplier Analysis
RMD Stock | USD 218.06 34.64 18.89% |
ResMed financial indicator trend analysis is much more than just breaking down ResMed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ResMed Inc is a good investment. Please check the relationship between ResMed Price To Sales Ratio and its Company Equity Multiplier accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Price To Sales Ratio vs Company Equity Multiplier
Price To Sales Ratio vs Company Equity Multiplier Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ResMed Inc Price To Sales Ratio account and Company Equity Multiplier. At this time, the significance of the direction appears to have weak relationship.
The correlation between ResMed's Price To Sales Ratio and Company Equity Multiplier is 0.35. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Company Equity Multiplier in the same time period over historical financial statements of ResMed Inc, assuming nothing else is changed. The correlation between historical values of ResMed's Price To Sales Ratio and Company Equity Multiplier is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of ResMed Inc are associated (or correlated) with its Company Equity Multiplier. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Company Equity Multiplier has no effect on the direction of Price To Sales Ratio i.e., ResMed's Price To Sales Ratio and Company Equity Multiplier go up and down completely randomly.
Correlation Coefficient | 0.35 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing ResMed Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ResMed sales, a figure that is much harder to manipulate than other ResMed Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Company Equity Multiplier
Most indicators from ResMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ResMed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, ResMed's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 451 M, whereas Issuance Of Capital Stock is forecasted to decline to about 48.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.0B | 2.4B | 2.7B | 2.8B | Total Revenue | 3.6B | 4.2B | 4.9B | 5.1B |
ResMed fundamental ratios Correlations
Click cells to compare fundamentals
ResMed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ResMed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.6B | 4.7B | 5.1B | 6.8B | 7.8B | 8.2B | |
Short Long Term Debt Total | 1.3B | 793.7M | 917.6M | 1.6B | 1.8B | 1.9B | |
Other Current Liab | 335.1M | 628.6M | 389.6M | 437.9M | 503.6M | 528.7M | |
Total Current Liabilities | 602.8M | 911.8M | 689.3M | 758.5M | 872.3M | 915.9M | |
Total Stockholder Equity | 2.5B | 2.9B | 3.4B | 4.1B | 4.7B | 5.0B | |
Property Plant And Equipment Net | 535.7M | 592.1M | 630.5M | 665.8M | 765.7M | 804.0M | |
Net Debt | 836.1M | 498.4M | 643.8M | 1.4B | 1.6B | 1.6B | |
Retained Earnings | 2.8B | 3.1B | 3.6B | 4.3B | 4.9B | 5.1B | |
Accounts Payable | 135.8M | 138.0M | 159.2M | 150.8M | 173.4M | 182.0M | |
Cash | 463.2M | 295.3M | 273.7M | 227.9M | 262.1M | 335.8M | |
Non Current Assets Total | 3.1B | 3.2B | 3.2B | 4.4B | 5.0B | 5.3B | |
Non Currrent Assets Other | 189.7M | 240.8M | 251.5M | 395.4M | 454.7M | 477.5M | |
Cash And Short Term Investments | 463.2M | 295.3M | 273.7M | 227.9M | 262.1M | 340.4M | |
Net Receivables | 474.6M | 614.3M | 576.0M | 704.9M | 810.6M | 851.2M | |
Common Stock Shares Outstanding | 145.7M | 146.5M | 147.0M | 147.5M | 169.6M | 147.3M | |
Liabilities And Stockholders Equity | 4.6B | 4.7B | 5.1B | 6.8B | 7.8B | 8.2B | |
Non Current Liabilities Total | 1.5B | 930.7M | 1.0B | 1.9B | 2.1B | 2.2B | |
Inventory | 416.9M | 457.0M | 743.9M | 998.0M | 1.1B | 1.2B | |
Other Current Assets | 168.7M | 208.2M | 337.9M | 437.0M | 502.6M | 527.7M | |
Other Stockholder Equity | (52.6M) | (1.1M) | 59.2M | 148.8M | 133.9M | 140.6M | |
Total Liab | 2.1B | 1.8B | 1.7B | 2.6B | 3.0B | 3.2B | |
Total Current Assets | 1.5B | 1.6B | 1.9B | 2.4B | 2.7B | 2.9B | |
Short Term Debt | 33.3M | 35.6M | 31.8M | 31.8M | 36.6M | 66.7M | |
Intangible Assets | 448.2M | 392.6M | 345.9M | 552.3M | 635.2M | 667.0M | |
Property Plant And Equipment Gross | 535.7M | 592.1M | 630.5M | 665.8M | 765.7M | 804.0M | |
Accumulated Other Comprehensive Income | (284.0M) | (193.5M) | (312.7M) | (272.5M) | (245.3M) | (233.0M) | |
Common Stock Total Equity | 571K | 575K | 580K | 583K | 670.5K | 417.0K | |
Common Stock | 580K | 583K | 586K | 588K | 676.2K | 435.6K | |
Other Assets | 145.6M | 240.8M | 202.3M | 261.3M | 300.5M | 315.5M | |
Good Will | 1.9B | 1.9B | 1.9B | 2.8B | 3.2B | 3.3B | |
Property Plant Equipment | 535.7M | 592.1M | 630.5M | 665.8M | 765.7M | 384.1M | |
Other Liab | 221.6M | 172.6M | 160.0M | 315.2M | 362.5M | 380.6M | |
Long Term Debt | 1.2B | 643.4M | 765.3M | 1.4B | 1.6B | 1.7B | |
Current Deferred Revenue | 98.6M | 109.6M | 108.7M | 138.1M | 158.8M | 166.7M | |
Net Tangible Assets | 158.5M | 565.2M | 1.1B | 807.3M | 726.5M | 632.7M | |
Long Term Debt Total | 1.3B | 1.2B | 643.4M | 765.3M | 880.1M | 737.7M | |
Capital Surpluse | 1.5B | 1.6B | 1.6B | 1.7B | 1.9B | 1.5B |
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.05 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.